AtriCure, Inc. 10-Q Summary: Quarter Ended September 30, 2010
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2010. AtriCure, Inc. is a medical device company developing and selling systems for the surgical ablation of cardiac tissue and the exclusion of the left atrial appendage. The company operates as a single reporting segment with sales in the United States and internationally. Key product lines include the Isolator Synergy bipolar ablation clamp system, cryoablation probes, and the AtriClip system, which received FDA clearance in June 2010.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Revenue | $14.47 million | $42.62 million |
| Gross Profit | $11.17 million | $33.08 million |
| Gross Margin | 77.2% | 77.6% |
| Net Loss | $(1.03) million | $(3.80) million |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.25) |
| Cash and Cash Equivalents | $3.53 million | $3.53 million (as of period end) |
| Short-Term Investments | $7.93 million | $7.93 million (as of period end) |
| Total Debt (Current + Long-Term) | $3.37 million | $3.37 million (as of period end) |
| Working Capital | $16.58 million | $16.58 million (as of period end) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9.0% for the quarter and 4.6% for the nine-month period compared to 2009. Growth was driven by the commercial launch of the AtriClip system and increased sales in direct European markets.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $1.0 million (quarterly) and $2.4 million (year-to-date), primarily due to increased headcount and costs associated with terminating a European distributor agreement.
- Non-Recurring Items: The prior year (2009) included a $6.8 million goodwill impairment charge and a $3.8 million settlement reserve charge, which significantly impacted the prior year's net loss. These items were absent in the 2010 periods.
- Cash Flow: Net cash used in operating activities was $1.6 million for the nine months ended September 30, 2010, compared to cash provided by operating activities of $0.3 million in the prior year period. The 2010 usage was driven by inventory build-up and accounts receivable growth.
Outlook, Risks, and Contingencies
- Regulatory Status: The company submitted a 510(k) filing for the Isolator Synergy system in April 2010 after FDA review. The company anticipates further communication in the fourth quarter of 2010. The DEEP AF clinical trial was approved by the FDA in September 2010.
- Legal Settlements: The company finalized a settlement with the Department of Justice (DOJ) in February 2010 totaling approximately $4.35 million (including interest), payable over five years. As of September 30, 2010, a liability of $3.08 million remained. Two securities class action lawsuits were settled in October 2010 for $2.0 million and $2.75 million, respectively, with the company expecting full insurance recovery.
- Liquidity: The company has approximately $8.0 million in unused borrowing capacity under its revolving credit facility. Management believes current cash and credit facilities are sufficient for operations for at least the next 12 months.
- Risks: Risks include the outcome of the 510(k) review for the Isolator Synergy system, the ability to secure regulatory approval for new products, and the impact of global economic conditions on elective surgical procedures.
Key Facts for Investor Verification
- Verify the status of the 510(k) submission for the Isolator Synergy system and the timeline for FDA clearance.
- Confirm the insurance recovery status for the two class action settlements finalized in October 2010.
- Monitor the enrollment progress of the DEEP AF clinical trial and the submission of the ABLATE PMA module.
- Review the impact of the European distributor termination on future revenue mix and gross margins in the Benelux region.
- Assess the company's ability to maintain compliance with financial covenants (minimum EBITDA, adjusted quick ratio) under its amended credit facility.